Exelixis, Inc. reported $2.44B of revenue over the trailing twelve months, +9.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.44B (to Q2 2026). Net income: $861M, trailing twelve months to Q2 2026. Free cash flow: $1.17B, trailing twelve months to Q2 2026. Operating margin: 40%, trailing twelve months to Q2 2026.

EXELExelixis, Inc.

Healthcare

$59.86+49% 1Y

$59.86

$34.5452 weeks$59.86

Latest close: a new 52-week highOct 9, 2026what changed →

EXEL as reported

Exelixis, Inc. reported $2.44B of revenue over the trailing twelve months, +9.2% on the year before. 11 reported series are charted on this page, each one as filed.

$2.44B

Revenue, trailing twelve months · to Q2 2026 · +9.2% against the twelve months before

Net income: $861M
Net income · +43% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.17B
Free cash flow · +55% year on year · trailing twelve months to Q2 2026
Operating margin: 40%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EXEL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.44B	+9.2%	Q2 2026
Net income	$861M	+43%	Q2 2026
EPS	$3.18	+53%	Q2 2026
Gross margin	96%	n/a	Q2 2026
Operating margin	40%	n/a	Q2 2026
Net margin	35%	n/a	Q2 2026
ROE	39%	n/a	Q2 2026
ROA	30%	n/a	Q2 2026
ROIC	−71%	n/a	Q4 2017 · 34 quarters behind
Free cash flow	$1.17B	+55%	Q2 2026
P/E	18.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.